{
    "id": 26162,
    "cites": 84,
    "cited_by": 2,
    "reference": [
        "Abaluck, J., L. Agha, C. Kabrhel, A. Raja, and A. Venkatesh, 2016: The Determinants of Productivity in Medical Testing: Intensity and Allocation of Care. American Economic Review, 106 (12), 3730\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c3764, doi:10.1257/aer.20140260, URL https://www.aeaweb.org/articles?id=10.1257/aer.20140260.",
        "Alexander, F., and Coauthors, 1999: 14 years of follow-up from the Edinburgh randomised trial of breastcancer screening. The Lancet, 353 (9168), 1903\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1908, doi:10.1016/S0140-6736(98)07413-3, URL http: //www.sciencedirect.com/science/article/pii/S0140673698074133.",
        "American Cancer Society, 2017a: Breast Cancer Facts & Figures 2017-2018. American Cancer Society, Inc., URL https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/ breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf.",
        "American Cancer Society, 2017b: Limitations of Mammograms. URL https://www.cancer.org/cancer/ breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html.",
        "American Cancer Society, 2018: History of ACS Recommendations for the Early Detection of Cancer in People Without Symptoms. URL https://www.cancer.org/ health-care-professionals/american-cancer-society-prevention-early-detection-guidelines/overview/ chronological-history-of-acs-recommendations.html.",
        "Anwar, S., and H. Fang, 2006: An Alternative Test of Racial Prejudice in Motor Vehicle Searches: Theory and Evidence. American Economic Review, 96 (1), 127\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c151, doi:10.1257/000282806776157579, URL https://www.aeaweb.org/articles?id=10.1257/000282806776157579.",
        "Berry, D., 2013: Breast cancer screening: Controversy of impact. Breast (Edinburgh, Scotland), 22 (0 2), S73\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cS76, doi:10.1016/j.breast.2013.07.013, URL https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4192714/.",
        "Bitler, M. P., and C. S. Carpenter, 2016: Health Insurance Mandates, Mammography, and Breast Cancer Diagnoses.",
        "Bjurstam, N., and Coauthors, 2003: The Gothenburg Breast Screening Trial. Cancer, 97 (10), 2387\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2396, doi:10.1002/cncr.11361, URL https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.11361.",
        "Bleyer, A., and H. G. Welch, 2012: Effect of three decades of screening mammography on breast-cancer incidence. The New England Journal of Medicine, 367 (21), 1998\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2005, doi:10.1056/NEJMoa1206809.",
        "Block, L., M. Jarlenski, A. Wu, and W. Bennett, 2013: Mammography use among women ages 40-49 after the 2009 u.s. preventive services task force recommendation. J Gen Intern Med, 28 (11), 1447\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1453.",
        "Blustein, J., 1995: Medicare Coverage, Supplemental Insurance, and the Use of Mammography by Older Women. New England Journal of Medicine, 332 (17), 1138\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1143, doi:10.1056/NEJM199504273321706, URL https://doi.org/10.1056/NEJM199504273321706.",
        "Brett, J., C. Bankhead, B. Henderson, E. Watson, and J. Austoker, 2005: The psychological impact of mammographic screening. A systematic review. Psycho-Oncology, 14 (11), 917\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c938, URL http://libproxy.mit.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true& db=mdc&AN=15786514&site=ehost-live&scope=site.",
        "Burstein, H. J., K. Polyak, J. S. Wong, S. C. Lester, and C. M. Kaelin, 2004: Ductal Carcinoma in Situ of the Breast. New England Journal of Medicine, 350 (14), 1430\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1441, doi:10.1056/NEJMra031301, URL https://doi.org/10.1056/NEJMra031301.",
        "Clarke, L. D., S. K. Plevritis, R. Boer, K. A. Cronin, and E. J. Feuer, 2006: Chapter 13: A Comparative Review of CISNET Breast Models Used To Analyze U.S. Breast Cancer Incidence and Mortality Trends.",
        "Cooper, G. S., T. D. Kou, A. Dor, S. M. Koroukian, and M. D. Schluchter, 2017: Cancer preventive services, socioeconomic status, and the Affordable Care Act. Cancer, 123 (9), 1585\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1589, doi:10.1002/cncr.30476.",
        "Cronin, K. A., and Coauthors, 2009: CEBP Focus on Cancer Surveillance: Bias Associated With SelfReport of Prior Screening Mammography. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 18 (6), 1699\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1705, doi:10.1158/1055-9965.EPI-09-0020, URL https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2771779/.",
        "Cutler, D. M., 2008: Are We Finally Winning the War on Cancer? Journal of Economic Perspectives, 22 (4), 3\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c26, doi:10.1257/jep.22.4.3, URL https://www.aeaweb.org/articles?id=10.1257/jep.22.4.3. Einav, L., A. Finkelstein, S. P. Ryan, P. Schrimpf, and M. R. Cullen, 2013: Selection on Moral Hazard in Health Insurance. American Economic Review, 103 (1), 178\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c219, doi:10.1257/aer.103.1.178, URL https://www.aeaweb.org/articles?id=10.1257/aer.103.1.178.",
        "Elmore, J. G., 2016: Solving the problem of overdiagnosis. New England Journal of Medicine, 375 (15), 1483\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1486, doi:10.1056/NEJMe1608683, URL https://doi.org/10.1056/NEJMe1608683, pMID: 27732826, https://doi.org/10.1056/NEJMe1608683.",
        "Ernster, V. L., and Coauthors, 2002: Detection of ductal carcinoma in situ in women undergoing screening mammography. Journal of the National Cancer Institute, 94 (20), 1546\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1554.",
        "Esserman, L., Y. Shieh, and I. Thompson, 2009: Rethinking screening for breast cancer and prostate cancer.",
        "Eusebi, V., E. Feudale, M. Foschini, A. Micheli, A. Conti, C. Riva, S. DiPalma, and F. Rilke, 1994: Longterm follow-up of in situ carcinoma of the breast. Seminars in Diagnostic Pathology, 11 (3), 223\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c235.",
        "Fedewa, S. A., and Coauthors, 2015: Elimination of cost-sharing and receipt of screening for colorectal and breast cancer. Cancer, 121 (18), 3272\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c3280, doi:10.1002/cncr.29494.",
        "Finkelstein, A., and Coauthors, 2012: The Oregon Health Insurance Experiment: Evidence from the First Year. The Quarterly Journal of Economics, 127 (3), 1057\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1106, doi:10.3386/w17190, URL http://www. nber.org/papers/w17190.",
        "Freeman, J., C. Klabunde, N. Schussler, J. Warren, B. Virnig, and G. Cooper, 2002: Measuring Breast, Colorectal, and Prostate Cancer Screening with Medicare Claims Data. Medical Care, 40 (8), (Supplement):IV\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c36\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cIV\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c42, URL https://journals.lww.com/lww-medicalcare/Abstract/2002/ 08001/Measuring_Breast,_Colorectal,_and_Prostate_Cancer.5.aspx.",
        "Fryback, D. G., N. K. Stout, M. A. Rosenberg, A. Trentham-Dietz, V. Kuruchittham, and P. L. Remington, 2006: The Wisconsin Breast Cancer Epidemiology Simulation Model. Journal of the National Cancer Institute. Monographs, (36), 37\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c47, doi:10.1093/jncimonographs/lgj007.",
        "Habbema, J. D. F., G. J. v. Oortmarssen, D. J. van Putten, J. T. Lubbe, and P. J. v. d. Maas, 1986: AgeSpecific Reduction in Breast Cancer Mortality by Screening: An Analysis of the Results of the Health Insurance Plan of Greater New York Study. JNCI: Journal of the National Cancer Institute, 77 (2), 317\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 320, doi:10.1093/jnci/77.2.317, URL https://academic.oup.com/jnci/article/77/2/317/945422.",
        "Habermann, E. B., B. A. Virnig, G. F. Riley, and N. N. Baxter, 2007: The impact of a change in Medicare reimbursement policy and HEDIS measures on stage at diagnosis among Medicare HMO and fee-for-service female breast cancer patients. Medical Care, 45 (8), 761\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c766, doi:10.1097/MLR. 0b013e3180616c51.",
        "Harding, C., F. Pompei, D. Burmistrov, H. G. Welch, R. Abebe, and R. Wilson, 2015: Breast Cancer Screening, Incidence, and Mortality Across US Counties. JAMA internal medicine, 175 (9), 1483\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1489, doi:10.1001/jamainternmed.2015.3043.",
        "HCCI, 2012: Health Care Cost and Utilization Report: 2011, URL https://www.nahdo.org/sites/nahdo.org/ files/publications/HCCI_HCCUR2011.pdf.",
        "Hubbard, R. A., K. Kerlikowske, C. I. Flowers, B. C. Yankaskas, W. Zhu, and D. L. Miglioretti, 2011: Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Annals of Internal Medicine, 155 (8), 481\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c492, doi:10.7326/ 0003-4819-155-8-201110180-00004.",
        "Hubbard, R. A., W. Zhu, S. Balch, T. Onega, and J. J. Fenton, 2015: Identification of abnormal screening mammogram interpretation using Medicare claims data. Health Services Research, 50 (1), 290\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c304, doi: 10.1111/1475-6773.12194.",
        "Humphrey, L. L., M. Helfand, B. K. S. Chan, and S. H. Woolf, 2002: Breast cancer screening: A summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 137 (5 Part 1), 347\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c360.",
        "Jacobson, M., and S. Kadiyala, 2017: When guidelines conflict: A case study of mammography screening initiation in the 1990s. Womens Health Issues, 27 (6), 692\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c699.",
        "J\u00c3\u0083\u00c2\u00b8rgensen, K. J., and P. C. G\u00c3\u0083\u00c2\u00b8tzsche, 2009: Overdiagnosis in publicly organised mammography screening programmes: Systematic review of incidence trends. BMJ, 339, b2587, doi:10.1136/bmj.b2587, URL https://www.bmj.com/content/339/bmj.b2587.",
        "J\u00c3\u0083\u00c2\u00b8rgensen, K. J., P. C. G\u00c3\u0083\u00c2\u00b8tzsche, M. Kalager, and P.-H. Zahl, 2017: Breast Cancer Screening in Denmark. Annals of Internal Medicine, 167 (7), 524, doi:10.7326/L17-0270, URL http://annals.org/article.aspx? doi=10.7326/L17-0270.",
        "Kadiyala, S., and E. Strumpf, 2011: Are United States and Canadian cancer screening rates consistent with guideline information regarding the age of screening initiation? International Journal for Quality in Health Care: Journal of the International Society for Quality in Health Care, 23 (6), 611\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c620, doi: 10.1093/intqhc/mzr050.",
        "Kadiyala, S., and E. Strumpf, 2016: How Effective is Population-Based Cancer Screening? Regression Discontinuity Estimates from the US Guideline Screening Initiation Ages. Forum for Health Economics & Policy, 19 (1), 87\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c139, URL https://ideas.repec.org/a/bpj/fhecpo/v19y2016i1p87-139n2.html.",
        "Kelaher, M., and J. M. Stellman, 2000: The impact of medicare funding on the use of mammography among older women: Implications for improving access to screening. Preventive Medicine, 31 (6), 658\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c664, doi: 10.1006/pmed.2000.0759.",
        "Kowalski, A. E., 2018: Behavior within a Clinical Trial and Implications for Mammography Guidelines. Working Paper 25049, National Bureau of Economic Research. doi:10.3386/w25049, URL http://www. nber.org/papers/w25049.",
        "Lu, Y., and D. J. G. Slusky, 2016: The Impact of Women\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Health Clinic Closures on Preventive Care.",
        "Maciosek, M. V., A. B. Coffield, T. J. Flottemesch, N. M. Edwards, and L. I. Solberg, 2010: Greater use of preventive services in u.s. health care could save lives at little or no cost. Health Affairs, 29 (9).",
        "Marmot, M. G., D. G. Altman, D. A. Cameron, J. A. Dewar, S. G. Thompson, and M. Wilcox, 2013: The benefits and harms of breast cancer screening: An independent review. British Journal of Cancer, 108 (11), 2205\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2240, doi:10.1038/bjc.2013.177, URL https://www.nature.com/articles/bjc2013177.",
        "Mehta, S. J., D. Polsky, J. Zhu, J. D. Lewis, J. T. Kolstad, G. Loewenstein, and K. G. Volpp, 2015: ACAmandated elimination of cost sharing for preventive screening has had limited early iimpact. The American Journal of Managed Care, 21 (7), 511\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c517.",
        "Miller, A. B., T. To, C. J. Baines, and C. Wall, 2000: The Canadian National Breast Screening Study-2: 13Year Results of a Randomized Trial in Women Aged 50\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c59 Years. JNCI: Journal of the National Cancer Institute, 92 (18), 1490\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1499, doi:10.1093/jnci/92.18.1490, URL https://academic.oup.com/jnci/article/ 92/18/1490/2909588.",
        "Miller, A. B., T. To, C. J. Baines, and C. Wall, 2002: The Canadian National Breast Screening Study-1: Breast Cancer Mortality after 11 to 16 Years of Follow-up: A Randomized Screening Trial of Mammography in Women Age 40 to 49 Years. Annals of Internal Medicine, 137 (5_Part_1), 305, doi: 10.7326/0003-4819-137-5_Part_1-200209030-00005, URL http://annals.org/article.aspx?doi=10.7326/ 0003-4819-137-5_Part_1-200209030-00005.",
        "Moss, S. M., H. Cuckle, A. Evans, L. Johns, M. Waller, and L. Bobrow, 2006: Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 follow-up: A randomised controlled trial. The Lancet, 368 (9552), 2053\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2060, doi:10.1016/S0140-6736(06)69834-6, URL http: //www.sciencedirect.com/science/article/pii/S0140673606698346.",
        "Nelson, H. D., K. Tyne, A. Naik, C. Bougatsos, B. K. Chan, and L. Humphrey, 2009: Screening for Breast Cancer: Systematic Evidence Review Update for the U. S. Preventive Services Task Force. Annals of internal medicine, 151 (10), 727\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cW242, doi:10.1059/0003-4819-151-10-200911170-00009, URL https: //www.ncbi.nlm.nih.gov/pmc/articles/PMC2972726/.",
        "Nystr\u00c3\u0083\u00c2\u00b6m, L., I. Andersson, N. Bjurstam, J. Frisell, B. Nordenskj\u00c3\u0083\u00c2\u00b6ld, and L. E. Rutqvist, 2002: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. The Lancet, 359 (9310), 909\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c919, doi:10.1016/S0140-6736(02)08020-0, URL http://www.sciencedirect.com/science/ article/pii/S0140673602080200.",
        "Oeffinger, K. C., and Coauthors, 2015: Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA, 314 (15), 1599\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1614, doi:10.1001/jama.2015. 12783, URL https://jamanetwork.com/journals/jama/fullarticle/2463262.",
        "Ong, M.-S., and K. D. Mandl, 2015: National expenditure for false-positive mammograms and breast cancer overdiagnoses estimated at $4 billion a year. Health Affairs (Project Hope), 34 (4), 576\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c583, doi:10.1377/ hlthaff.2014.1087.",
        "Oster, E., 2018: Behavioral Feedback: Do Individual Choices Influence Scientific Results? Working Paper 25225, National Bureau of Economic Research. doi:10.3386/w25225, URL http://www.nber.org/papers/ w25225.",
        "Page, D., W. Dupont, L. Rogers, R. Jensen, and P. Schuyler, 1995: Contined local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy.",
        "Persico, N., 2009: Racial profiling? detecting bias using statistical evidence. Annual Review of Economics, 1 (1), 229\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c254, doi:10.1146/annurev.economics.050708.143307, URL https://doi.org/10.1146/annurev. economics.050708.143307, https://doi.org/10.1146/annurev.economics.050708.143307.",
        "Rosenberg, M. A., 2006: Competing risks to breast cancer mortality. Journal of the National Cancer Institute.",
        "Roth, M. Y., J. G. Elmore, J. P. Yi-Frazier, L. M. Reisch, N. V. Oster, and D. L. Miglioretti, 2011: Selfdetection remains a key method of breast cancer detection for U.S. women. Journal of Women\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Health (2002), 20 (8), 1135\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1139, doi:10.1089/jwh.2010.2493.",
        "Saad, L., 2009: Women Disagree with New Mammogram Advice. Gallup, URL http://news.gallup.com/ poll/124463/women-disagree-new-mammogram-advice.aspx.",
        "Schousboe, J., K. Kerlikowske, A. Loh, and S. Cummings, 2011: Personalizing mammography by breast density and other risk factors for breast cancer: Analysis of health benefits and cost-effectiveness. Annals of Internal Medicine, 155 (1), 10\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c20.",
        "SEER, 2019: SEER Incidence Data, 1973-2015. URL https://seer.cancer.gov/data/index.html.",
        "Segel, J., R. Balkrishnan, and R. Hirth, 2017: The Effect of False-positive Mammograms on Antidepressant and Anxiolytic Initiation. Medical Care, 55 (8), 752\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c758, URL https://journals.lww.com/ lww-medicalcare/Abstract/2017/08000/The_Effect_of_False_positive_Mammograms_on.3.aspx.",
        "Susan G. Komen Foundation, 2018: Accuracy of Mammograms. URL https://ww5.komen.org/ BreastCancer/AccuracyofMammograms.html.",
        "Tan, S. Y. G. L., G. J. van Oortmarssen, H. J. de Koning, R. Boer, and J. D. F. Habbema, 2006: The MISCAN-Fadia Continuous Tumor Growth Model for Breast Cancer. JNCI Monographs, 2006 (36), 56\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c65, doi:10.1093/jncimonographs/lgj009, URL https://academic.oup.com/jncimono/article/2006/36/ 56/917299.",
        "Taubes, G., 1997: The Breast-Screening Brawl. Science, 275 (5303), 1056\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1059, doi:10.1126/science.275. 5303.1056, URL http://science.sciencemag.org/content/275/5303/1056.",
        "Welch, H. G., 2015: Less Medicine, More Health: 7 Assumptions That Drive Too Much Medical Care. Beacon Press.",
        "Welch, H. G., and W. C. Black, 2010: Overdiagnosis in Cancer. JNCI: Journal of the National Cancer Institute, 102 (9), 605\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c613, doi:10.1093/jnci/djq099, URL https://academic.oup.com/jnci/article/102/9/ 605/894608.",
        "Welch, H. G., and H. J. Passow, 2014: Quantifying the benefits and harms of screening mammography.",
        "Welch, H. G., P. C. Prorok, A. J. O\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2Malley, and B. S. Kramer, 2016: Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. New England Journal of Medicine, 375 (15), 1438\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1447, doi:10.1056/NEJMoa1600249, URL https://doi.org/10.1056/NEJMoa1600249.",
        "Welch, H. G., L. M. Schwartz, and S. Woloshin, 2011: Overdiagnosed: Making People Sick in the Pursuit of Health. Beacon Press.",
        "Zackrisson, S., I. Andersson, L. Janzon, J. Manjer, and J. P. Garne, 2006: Rate of over-diagnosis of breast cancer 15 years after end of Malm\u00c3\u0083\u00c2\u00b6 mammographic screening trial: Follow-up study. BMJ, 332 (7543), 689\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c692, doi:10.1136/bmj.38764.572569.7C, URL https://www.bmj.com/content/332/7543/689.",
        "Zahl, P.-H., J. M\u00c3\u0083\u00c2\u00a6hlen, and H. G. Welch, 2008: The Natural History of Invasive Breast Cancers Detected by Screening Mammography. Archives of Internal Medicine, 168 (21), 2311\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2316, doi:10.1001/archinte.",
        "Figure 3: Tumor stage and size by age 20 22 24 26 28 30 32 0.08 0.11 0.14 0.17 0.2 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 Average detected tumor size (mm) Share of detected tumors that are in situ Age Share in situ (primary y\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u0090axis) Average tumor size (secondary y\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u0090axis) Notes: Figure shows diagnosed breast cancer tumors in the SEER (2000-2014) data by age. Primary y-axis shows share of breast cancer tumors that are in situ. Secondary y-axis shows average size of diagnosed tumors. Error bars reflect 95% confidence intervals. N =197,956 breast cancer diagnoses.",
        "The linked SEER-Medicare data allows us to cross validate this claims-based coding process against 18Segel, Balkrishnan\u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u00be and Hirth (2017) focused on data from 2003-2004, so used the CPT code 76092. In 2007 this code was replaced by 77057. In addition, Hubbard et al. (2015) identify CPT code G0202 as indicating a screening mammogram claim.",
        "As described in the main text, the Erasmus model is one of seven models developed for the Cancer Intervention and Surveillance Modeling Network (CISNET) as part of a project decomposing breast cancer mortality reductions from 1975-2000 into effects from the dissemination of mammography versus the development of advanced treatment techniques (Clarke et al. 2006). Each of the groups participating in the project wrote a model of breast cancer incidence and mortality in the US over this time period and then compared the mortality rates under scenarios with and without mammography and advanced treatment. For convenience, we focus on one of these models, the Erasmus model (Tan et al., 2006).",
        "(2006), the other-cause death probability follows the approach of Rosenberg (2006). However, we adjusted the tumor incidence parameters (overall cohort incidence and quadratic incidence by age) that are given in Tan et al. (2006) in order to match the SEER data\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s share of diagnoses that are in situ and invasive for those under 40 and over 40. After establishing these population-specific parameters, we simulate individual life histories under a no-screening assumption, and use the tumor sizes and types to determine the population cancer rate by age.",
        "Other-cause death probability Following Rosenberg (2006), we computed probability of death due to other causes as the difference between the all-cause mortality and breast cancer specific mortality. We obtained all-cause mortality for ages 0-110 and years 1933-2010 from the Human Mortality Database. Using breast cancer death totals from the National Center for Health Statistics and female population totals from the Human Mortality Database, we calculated breast-cancer-specific mortality for ages 0-110 and years 1959-2010. To impute values for previous years, we assumed that the age-specific breast cancer mortality rate in any year before 1958 was equal to the rate in 1958. We combined these data to calculate non-breast-cancer mortality rates for all years between 1933 and 2010.",
        "Appendix Figure A.8 plots the share of women in each of five categories when the Erasmus model is calculated with no screening. The calculation is based on birth cohorts from 1950-1975, and focuses on women aged 30-50 in 2000-2005. At any given age, the share of women with detectable invasive or DCIS cancer is substantially smaller than the share of women who have already been diagnosed clinically, indicating that there is a small window of time during which a cancer can be screened before it is clinically detected.",
        "Two specifications test sensitivity to decreasing the share of in-situ tumors that become invasive. The Erasmus model assumes that 62.5% of in-situ tumors will become invasive, while estimates for the fraction of DCIS tumors that would become invasive over 10 years if left untreated ranges from 14-60% (Burstein et al., 2004), putting the Erasmus model at the most conservative end of the spectrum. Alternate estimates suggest that the share of DCIS-tumors that become invasive is 14% (Eusebi et al., 1994) or 28% (Page et al., 1995). In these checks, we also shift the tumor type distribution to match these estimates at age 40. This sensitivity proportionally reduces the share of DCIS-invasive tumors at all ages, and proportionally increases the share of tumors that are DCIS-regressive and DCIS-clinical at all ages. The share of invasive tumors remains the same.",
        "In an alternate natural history model (Fryback et al., 2006), the share of tumors with \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093non-malignant potential\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d was 42%. Alternate estimates of over-diagnosis are provided by three trials in which women in the control group were not invited to be screened at the end of the active trial period. In a meta-analysis, estimates of the excess incidence was 19% when expressed as a proportion of the cancers diagnosed during the active screening period (Marmot et al., 2013). We therefore increase the share of non-malignant tumors from approximately 8% at age 40 to (separately) 19% and 42% at age 40. In each of these sensitivity analyses, we increase the share of DCIS-regressive and DCIS-clinical at all ages in a proportional shift so that the share of non-malignant tumors at age 40 is either 19% or 42%. We separately decrease the share of tumors that are invasive or DCIS-invasive by a proportional shift so that the total tumor types sum to 100%.",
        "Num per 1000 alive in cohort 25 30 35 40 45 50 55 60 Age at diagnosis/incidence SEER Dx Sim Dx Sim Incd (a) Original incidence 0 2 4 6 8",
        "Table A.1: Codes used to identify claims Event Code type CPT Codes ICD-9 Codes Screening mammogram CPT procedure 77057*, G0202** V76.12 Breast biopsy CPT procedure 19100, 19101, 19120 85.11, 85.12, 85.20, 85.21 Breast ultrasound CPT procedure 76645 88.73** Radiologic breast testing CPT procedure 76003, 77002*, 76095, 77031*, 76086, 76087, 76088, 77053*, 77054*, 76355, 76360, 76362, 77011*, 77012*, 77013*, 76098, 76100, 76101, 76102, 76120, 76125, 76140, 76150, 76350, 76365 87.35, 87.36, 87.73, 88.85 Breast cancer treatment CPT procedure 19160, 19162, 19180, 19200, 19220, 19240, 19301**, 19303**, 19305**, 19307**, 38740, 38745 233.0, V103.0, 174.0-174.9 * indicates this code was not provided by Segel, Balkrishnan\u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u00be and Hirth (2017) but is the post-2007 analog of such a code. See http://provider.indianamedicaid.com/ihcp/Bulletins/BT200701.pdf.",
        "** indicates this code was provided by Hubbard et al. (2015) rather than Segel, Balkrishnan\u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u00be and Hirth (2017). Notes: This table provides the codes used to define mammograms in the HCCI and SEER-Medicare claims data. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093CPT codes\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d are also known as \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093HCPCS codes\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d.",
        "Table A.5: Model parameters All women Notation Values Probability of death from other causes Qb y Derived following Rosenberg (2006) Probability of any breast cancer Cb Quadratic fit to Table A.8 plus further optimization Age-specific probability of onset (given any onset) Sa Quadratic fit to values in Table A.6 Probability of invasive tumor (given tumor onset) Ia See Table A.9 Probability of DCIS tumor sub-type (summing to 1 - Ia) Va,Ra,Ca See Table A.9 Invasive Tumors Mean of log of growth rate gi G 0.062 SD of log of growth rate gi \u00c3\u008f\u00c6\u0092G 0.87 Scale parameter for screen detection ray i \u00c3\u008e\u00c2\u00b2ay R see Table A.7 Shape parameter for screen detection ray i",
        "\u00c3\u008e\u00c2\u00b7R 2.95 Mean of log of clinical diagnosis diameter ci C 0.97 SD of log of clinical diagnosis diameter ci \u00c3\u008f\u00c6\u0092C 0.63 Scale parameter for fatal diameter fi \u00c3\u008e\u00c2\u00b2y F Linear between 1915 and 1975 (0.8 in 1915; 4.0 in 1975); 4.0 after 1975 Shape parameter for fatal diameter fi \u00c3\u008e\u00c2\u00b7F 0.95 Mean of log of survival duration ui U 2.43 SD of log of survival duration ui \u00c3\u008f\u00c6\u0092U 1.13 Correlation between gi and ci \u00c3\u008f\u00c2\u0081gc +0.41 Correlation between gi and ui \u00c3\u008f\u00c2\u0081gu-0.90 Correlation between ci and ui \u00c3\u008f\u00c2\u0081cu-0.43 DCIS Tumors Mean of tumor dwell time wi 21 W 5.22 - (time to grow from 1975 to current year screening diameter) Screening sensitivity Ey Linear from 1975-2000 (0.4 in 1975, 0.8 in 2000) and 0.8 from 2001-2010 Note: This table lists the parameters of the tumor growth model, along with their values where applicable.",
        "21Dwell time wi (time from in situ onset to invasive onset) is calculated by subtracting the time it takes the invasive tumor to grow from the 1975 screening threshold to the current screening threshold from a random draw from an exponential distribution with mean 5.22."
    ]
}